158
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Evaluating the Feasibility of a Community Pharmacy-Delivered Behaviour Change Intervention to Reduce Reliever Reliance in Asthma

, ORCID Icon, , , ORCID Icon &
Pages 361-371 | Received 20 Oct 2023, Accepted 31 Jan 2024, Published online: 07 Feb 2024

References

  • Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma; 2019.
  • Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:10.1183/13993003.01872-2019
  • FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–140. doi:10.1016/j.rmed.2017.08.014
  • Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-The-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7(9):e016688. doi:10.1136/bmjopen-2017-016688
  • Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM. Has asthma medication use caught up with the evidence?: A 12-year population-based study of trends. Chest. 2017;151(3):612–618. doi:10.1016/j.chest.2016.10.028
  • Atlas of Healthcare Variation Asthma. Health quality & safety commission New Zealand; 2018. Available from: https://public.tableau.com/profile/hqi2803#!/vizhome/Asthmasinglemap2018/AtlasofHealthcareVariationAsthma?publish=yes. Accessed October 13, 2020.
  • Boulet LP, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clinics Chest Med. 2012;33(3):405–417. doi:10.1016/j.ccm.2012.06.002
  • Cole S, Seale C, Griffiths C. ‘The blue one takes a battering’ why do young adults with asthma overuse bronchodilator inhalers? A qualitative study. BMJ Open. 2013;3(2):e002247. doi:10.1136/bmjopen-2012-002247
  • Kelly MP, Barker M. Why is changing health-related behaviour so difficult? Public Health. 2016;136:109–116. doi:10.1016/j.puhe.2016.03.030
  • Østrem A, Horne R. Reducing asthma attacks: consider patients’ beliefs. Npj Primary Care Respiratory Medicine. 2015;25(1):15021. doi:10.1038/npjpcrm.2015.21
  • Lycett H, Wildman E, Raebel EM, Sherlock JP, Kenny T, Chan AHY. Treatment perceptions in patients with asthma: synthesis of factors influencing adherence. Respir Med. 2018;141:180–189. doi:10.1016/j.rmed.2018.06.032
  • Chan AHY, Katzer C, Kaplan A, et al. SABA Reliance Questionnaire (SRQ): identifying patient beliefs underpinning reliever over-reliance in asthma. J All Clin Immunol in Practice. 2020;8:3482–3489.e1. doi:10.1016/j.jaip.2020.07.014
  • Chan AHY, Horne R, Hankins M, Chisari C. The medication adherence report scale: a measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharmacol. 2020;86(7):1281–1288. doi:10.1111/bcp.14193
  • Horne R, Chan A, Haughney J, Correia De Sousa J, Williams S, Kaplan A. Late breaking abstract - identifying and addressing patient beliefs driving SABA use and over-reliance. Eur Respir J. 2019;54(suppl 63):OA5333.
  • Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
  • Foot H, Beyene K, Horne R, Fingleton J, Harrison J, Chan A. A study protocol for a feasibility trial in community pharmacy of a personalised behaviour change intervention to reduce reliever reliance and overuse in individuals with asthma. Protoc Exch. 2021;2021:1.
  • Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Primary Care Respirat J. 2009;18(1):41–49. doi:10.4104/pcrj.2009.00010
  • International Primary Care Respiratory Group. Blue reliever reliance test; 2020. Available from: https://www.ipcrg.org/resources/search-resources/reliever-reliance-test-english. Accessed September 18, 2020.
  • Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.0080633
  • Foot H, La Caze A, Gujral G, Cottrell N. The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ Couns. 2016;99(5):706–717. doi:10.1016/j.pec.2015.11.004
  • Horne R, Cooper V, Wileman V, Chan A. Supporting adherence to medicines for long-term conditions: a perceptions and practicalities approach based on an extended common-sense model. Eur Psychol. 2019;24(1):82–96. doi:10.1027/1016-9040/a000353
  • Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88. doi:10.1186/s12913-017-2031-8
  • Orsmond GI, Cohn ES. The distinctive features of a feasibility study: objectives and guiding questions. OTJR. 2015;35(3):169–177. doi:10.1177/1539449215578649
  • Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom clinical research network database. BMC Med Res Method. 2013;13:104. doi:10.1186/1471-2288-13-104
  • Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287–291. doi:10.1002/pst.185
  • Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237–246. doi:10.1177/1098214005283748
  • Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026. doi:10.1038/npjpcrm.2015.26
  • Blakeston S, Harper G, Zabala Mancebo J. Identifying the drivers of patients’ reliance on short-acting β2-agonists in asthma. J Asthma. 2020;2020:1–8.
  • Khayyat S, Walters P, Whittlesea C, Nazar H. Patient and public perception and experience of community pharmacy services post-discharge in the UK: a rapid review and qualitative study. BMJ Open. 2021;11(3):e043344. doi:10.1136/bmjopen-2020-043344
  • Bertilsson E, Serhal S, Emmerton L, et al. Pharmacists experience of and perspectives about recruiting patients into a community pharmacy asthma service trial. Res Social Administrative Pharm. 2021;17(3):595–605. doi:10.1016/j.sapharm.2020.05.012
  • Hossain LN, Tudball J, Franco-Trigo L, Durks D, Benrimoj SI, Sabater-Hernández D. A multilevel stakeholder approach for identifying the determinants of implementation of government-funded community pharmacy services at the primary care level. Res Social Administrative Pharm. 2018;14(8):765–775. doi:10.1016/j.sapharm.2017.10.001